Gastroenterology

Top Medical News
Specific carbohydrate diet may improve symptoms for some IBD patients
6 hours ago
A specific carbohydrate diet (SCD) and a modified SCD (MSCD) demonstrate inconsistent effectiveness for the improvement of symptoms in inflammatory bowel disease (IBD), with some patients benefitting and others not, reports a study.
Colorectal cancer alters gut microbiome
Tristan Manalac, 2 days ago
Patients with colorectal cancer (CRC) have a substantially altered gut microbiome, characterized by changes in bacterial composition, according to a recent Singapore study. Of note, these alterations persist even after surgery.
H. pylori eradication: Triple therapy with 1-week vonoprazan as good as with 2-week PPI
2 days ago
One-week vonoprazan-based triple therapy is well tolerated and has comparable efficacy as the 2-week proton pump inhibitor (PPI)-based triple therapy for first-line Helicobacter pylori eradication, according to a study.
Is endoscopic submucosal dissection safe for rectal tumours extending to dentate line?
3 days ago
Treatment with endoscopic submucosal dissection (ESD) for rectal tumours extending to the dentate line (RTDLs) remains safe and feasible despite its poorer outcomes relative to non-RTDLs if appropriate lesions are handled by experienced operators, suggests a study.
Appendectomy carries modest risk of microscopic colitis
3 days ago
Undergoing appendectomy may put patients at risk of developing subsequent microscopic colitis, although the risk increase appears to be modest, as shown in a study.
Aminosalicylate use more common among older than younger IBD patients
4 days ago
Use of medication is markedly different among older patients with inflammatory bowel disease (IBD), with more aminosalicylate monotherapy and less antitumour necrosis factor monotherapy than younger patients, according to a US study.
Dostarlimab in rectal cancer: are we inching towards a cure?
Audrey Abella, 4 days ago
In what has been dubbed as ‘a small but mighty study’ at ASCO 2022, a phase II trial spearheaded by investigators from Memorial Sloan Kettering Cancer Center in New York, US heralded the remarkable efficacy and safety of the monoclonal antibody dostarlimab for the treatment of locally advanced mismatch repair-deficient (dMMR) rectal cancer.

Special Reports
Product Highlight - Salofalk
12 Mar 2021
SALOFALK – Mesalazine 1.5 g PR granules
Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Role of genomics in colorectal cancers
Dr Joslyn Ngu, 04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

Product Highlight – Dukoral
12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
Conference Reports
Mirikizumab maintenance eases bothersome symptoms of UC
Elvira Manzano, 09 Jun 2022
Maintenance therapy with the anti-IL-23p19 antibody mirikizumab boosts clinical benefits in moderate-to-severe ulcerative colitis (UC) in the phase III LUCENT-2 trial, improving bowel urgency that is not only disruptive but likewise embarrassing for patients.
PPIs misused in treatment of lower gastrointestinal bleeding
Tristan Manalac, 08 Jun 2022
Despite no other indication or proven clinical benefit, proton pump inhibitors (PPIs) are frequently inappropriately used to treat lower gastrointestinal bleeding (LGIB), according to a study presented at the recently concluded 2022 Digestive Disease Week (DDW 2022).
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
Jairia Dela Cruz, 07 Jun 2022
The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.
Tenapanor improves symptoms in patients with IBS-C
Elaine Soliven, 07 Jun 2022
Treatment with tenapanor improves symptoms in patients with irritable bowel syndrome with constipation (IBS-C) as early as week 1 of treatment, according to two phase III studies presented at DDW 2022.
Antibiotics identified as culprit for older-onset IBD
Jairia Dela Cruz, 06 Jun 2022
Antibiotic use appears to be harmful for older adults, with a recent study showing that regardless of class, the drugs raise the risk of developing inflammatory bowel disease (IBD).
NAFLD tied to CVD risk even in lean patients
Elvira Manzano, 06 Jun 2022
Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.
Statin use lowers all-cause mortality in colorectal cancer
Stephen Padilla, 03 Jun 2022
Use of statins results in reduced all-cause mortality in nearly 30,000 veterans with colorectal cancer (CRC), results of a study have shown.